iZumi: Phenotypic assays

It's a common lament that animal models and cell-based assays poorly predict safety and efficacy in the clinic. iZumi Bio Inc. aims to improve over these models by creating induced pluripotent stem cells from specific patient populations for use in drug discovery.

Because iPS cells derived from patients can be redifferentiated into cell types that better represent disease phenotypes, the company believes they will be more predictive of a compound's activity in the clinic...